1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends

Competitor Analysis: TNF Antibodies –Biosimilars and Biosuperiors

  • February 2014
  • 98 pages
  • La Merie Publishing
Report ID: 1054397

Summary

Table of Contents

Search Inside

TNF Antibodies –Biosimilars and Biosuperiors
The present Competitive Intelligence Report about TNF Antibodies –Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting tumor necrosis factor (TNF) alpha or its receptor used to treat various inflammatory and autoimmune diseases as of March 2014. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The therapeutic drug class of TNF antibodies presently consists of five different approved and marketed products which all together achieved worldwide sales of US$ 30.5 bln in 2013. Among the approved indications for use of TNF antibodies in general are rheumatoid arthritis, idiopathic juvenile arthritis (JIA), psoriatic arthritis, ankylosing spondylitis, psoriasis, ulcerative colitis and Crohn’s disease. However, not all TNF antibodies are the same and their efficacy had to be demonstrated for each indication.
The highly attractive market and the forthcoming expiration of patents has attracted biosuperior as well as biosimilar antibodies. For all of the five marketed TNF antibodies are biosimilar molecules in the R&D pipeline, but with clear priority on the first generation TNF antibody constructs.
The report includes a compilation of currently active projects in development of TNF targeting antibodies for treatment of inflammatory and autoimmune diseases. In addition, the report lists company-specific R&D pipelines of TNF antibodies. Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Amrita helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Erythropoietin (EPO) Drugs Market Analysis By Drug Class (Biologics, Biosimilars), By Product (Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa, Others), By Application, And Segment Forecasts, 2014 - 2025

  • $ 4950
  • Industry report
  • May 2017
  • by Grand View Research

The global erythropoietin (EPO) drugs market is expected to reach USD 17.4 billion by 2025, according to a new report by Grand View Research, Inc. Rising incidence of chronic diseases such as CKD and cance ...

Global Biosimilars Market

  • $ 4250
  • Industry report
  • July 2017
  • by Mordor Intelligence LLP

The global biosimilar market was estimated to be USD XX million in 2016 and is expected to reach USD XX million by 2021, witnessing a CAGR of XX% during the forecast period. Biosimilar is a biological ...

Japan Biosimilars – A start of Authorized Biosimilar Era? - Biosimilar/BioPharma CMO opportunities – JP Conglomerates – A definite role to play for Global Market!

  • $ 4000
  • Industry report
  • August 2017
  • by MP Advisors

Major JP Innovator vs. Early entrant Mid size Japanese companies- TA focus approach – A Win Win Game! In this report, we attempt to evaluate key upcoming opportunity for Japan BS market, its competitive ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.